Global Indomethacin Market Size To Worth USD 2.01 Billion By 2033 | CAGR of 6.41%
Category: HealthcareGlobal Indomethacin Market Worth USD 2.01 Billion By 2033
According to a Research Report Published By Spherical Insights & Consulting, the Global Indomethacin Market Size is Expected to Grow from USD 1.08 Billion in 2023 to USD 2.01 Billion by 2033, at a CAGR of 6.41% during the forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 160 pages with 110 Market data tables and figures & charts from the report on the " Global Indomethacin Market Size, Share, and COVID-19 Impact Analysis, By Dosage Form (Suppositories, Injections, Capsules, Suspension, and Others), By Indications (Osteoarthritis, Gout, Ankylosing Spondylitis, Rheumatoid Arthritis, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023-2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/indomethacin-market
The global indomethacin market focuses on the development, production, and commercialization of indomethacin and its medications for pain and inflammation conditions like gout, arthritis, and ankylosing spondylitis. Indomethacin, a class of potent NSAIDs, is FDA-approved for treating mild to moderate acute pain and relieving symptoms of arthritis or gout. It inhibits prostaglandin synthesis, crucial for inflammation, fever, and pain. The increasing prevalence of inflammatory diseases has led to the need for nonsteroidal anti-inflammatory medications like indomethacin for treating osteoarthritis and rheumatoid arthritis. The market expansion is driven by various government initiatives, such as the National Programme for Health Care of the Elderly (NPHCE), Affordable Medicines and Reliable Implants for Treatment (AMRIT) Deendayal outlets, Jan Aushadhi stores, and the Pradhan Mantri Jan Arogya Yojna (PMJAY), which provide cashless access to services in empanelled hospitals across India. However, side effects may impede market growth.
The capsules segment held a substantial share in 2023 and is predicted to grow at a significant CAGR during the predicted period.
Based on the dosage form, the global indomethacin market is categorized as suppositories, injections, capsules, suspension, and others. Among these, the capsules segment held a substantial share in 2023 and is predicted to grow at a significant CAGR during the predicted period. The expansion in the segment is attributed to patient compliance, ease of administration, enhanced bioavailability, and the availability of a novel drug delivery system.
The rheumatoid arthritis segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the indications, the global indomethacin market is categorized as osteoarthritis, gout, ankylosing spondylitis, rheumatoid arthritis, and others. Among these, the rheumatoid arthritis segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The sector's growth is attributed to rising rheumatoid arthritis cases, indomethacin's efficacy, inflammatory conditions, genetic predisposition, and immune system dysregulation.
The hospital pharmacies segment accounted for a substantial share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the distribution channel, the global Indomethacin market is categorized as retail pharmacies, hospital pharmacies, online pharmacies, and others. Among these, the hospital pharmacies segment accounted for a substantial share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment's growth is attributed to personalized medication, skilled pharmacists, cost-effective options, and a wide range of indomethacin products.
North America is expected to hold the greatest share of the global indomethacin market over the forecast period.
Get more details on this report -
North America is expected to hold the greatest share of the global indomethacin market over the forecast period. The indomethacin market in North America is expanding due to high rates of arthritis, a robust healthcare system, substantial healthcare spending, large pharmaceutical firms, and research efforts. The growing older population and increased health consciousness are driving patients to seek effective treatments, benefiting the market as it is widely available across hospitals, clinics, and pharmacies.
Asia Pacific is predicted to grow at the fastest throughout the estimated period. The Asia Pacific market for indomethacin is expanding due to increased healthcare spending, improved infrastructure, and increased awareness of effective treatments. Countries like China, India, and Japan are contributing to this growth. Strategic partnerships with local healthcare providers ensure indomethacin is accessible to a larger patient population. Economic growth promotes improved healthcare systems and access to medications, particularly in rural areas. Policies enhancing healthcare accessibility and awareness indirectly drive market growth.
Major key players in the global indomethacin market are Hikma Pharmaceuticals PLC, Cipla Inc., Endo Pharmaceuticals Inc., Zydus Cadila, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Amneal Pharmaceuticals LLC, Lupin Limited, Sandoz International GmbH, Novartis AG, Alkem Laboratories Ltd., Apotex Inc., Teva Pharmaceutical Industries Ltd., Glenmarke Pharmaceuticals Ltd., and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In December 2024, Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, developed Indomethacin Suppositories (50mg) dose making it the second generic on the market. The product is indicated for moderate to severe rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and acute gouty arthritis. This expansion broadens the choice of medicines available to doctors and patients in the US.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global indomethacin market based on the below-mentioned segments:
Global Indomethacin Market, By Dosage Form
- Suppositories
- Injections
- Capsules
- Suspension
- Others
Global Indomethacin Market, By Indications
- Osteoarthritis
- Gout
- Ankylosing Spondylitis
- Rheumatoid Arthritis
- Others
Global Indomethacin Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Others
Global Indomethacin Market, By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?